Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Beractant
Drug ID BADD_D00255
Description Beractant is a pulmonary surfactant used for the treatment of Respiratory Distress Syndrome (RDS) in premature infants. Considered a natural source of surfactant as it is made from bovine lung extract, beractant contains a mixture of phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins such as SP-B and SP-C. The final composition provides 25 mg/mL phospholipids (including 11.0-15.5 mg/mL disaturated phosphatidylcholine), 0.5-1.75 mg/mL triglycerides, 1.4-3.5 mg/mL free fatty acids, and less than 1.0 mg/mL protein. It is suspended in 0.9% sodium chloride solution, and heat-sterilized. In anticipation of birth, endogenous lung surfactant is produced to lower the surface tension on alveolar surfaces and to stabilize the alveoli against collapse at resting transpulmonary pressures. However, in Respiratory Distress Syndrome, developmental deficiency of surfactant results collapse of the alveoli causing fast breathing, increased heart rate, apoxia, and sometimes death. Administration of lung surfactant remains the cornerstone of therapy in this condition that is currently the leading cause of death in preterm infants. In comparison to synthetic forms of surfacant, natural forms such as Beractant have been found to have a reduced incidence of pneumothorax and reduced mortality.
Indications and Usage Beractant is indicated for prevention and treatment of Respiratory Distress Syndrome (RDS) in premature infants.
Marketing Status Prescription
ATC Code Not Available
DrugBank ID DB06761
KEGG ID D03096
MeSH ID C072197
PubChem ID Not Available
TTD Drug ID D02VLX
NDC Product Code 0074-1040
Synonyms beractant | surfactant-TA | Survanta
Chemical Information
Molecular Formula Not Available
CAS Registry Number 108778-82-1
SMILES Not Available
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pyrexia08.05.02.003--
Renal failure20.01.03.005--Not Available
Respiratory failure22.02.06.002; 14.01.04.003--
Seizure17.12.03.001--
Sepsis11.01.11.003--
Stress ulcer07.04.04.007--Not Available
Tachycardia02.03.02.007--Not Available
Thrombocytopenia01.08.01.002--Not Available
Vasoconstriction24.04.03.008; 23.06.05.007--Not Available
Ventricular tachycardia02.03.04.010--
Volvulus07.13.01.012--Not Available
General physical health deterioration08.01.03.018--Not Available
Neonatal hypoxia22.11.02.002; 18.04.15.002--Not Available
Necrotising colitis07.08.01.013--Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.001--Not Available
Haemorrhage24.07.01.002--Not Available
Anomalous pulmonary venous connection24.03.03.006; 03.07.04.001; 02.08.02.002--Not Available
Endotracheal intubation complication08.07.02.001; 22.04.07.001; 12.02.07.002--Not Available
Pulmonary air leakage22.01.02.011; 18.04.09.001; 12.02.07.004--Not Available
Feeding intolerance18.04.11.003; 14.02.01.006--Not Available
The 2th Page    First    Pre   2    Total 2 Pages